Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling

Javier Barallobre-Barreiro, PhD; Tamás Radovits, MD, PhD; Marika Fava, PhD; Ursula Mayr, MD; Wen-Yu Lin, MD; Elizaveta Ermolaeva, MSc; Diego Martínez-López, PhD; Eric L. Lindberg, MSc; Elisa Duregotti, PhD; László Daróczi, MD; Maria Hasman, MSc; Lukas E. Schmidt, MSc; Bhawana Singh, MSc; Ruifang Lu, PhD; Ferheen Baig, PhD; Aleksandra Malgorzata Siedlar, PhD; Friederike Cuello, PhD; Norman Catibog, RDCS; Konstantinos Theofilatos, PhD; Ajay M. Shah, FMedSci; Maria G. Crespo-Leiro, MD, PhD; Nieves Doménech, PhD; Norbert Hübner, MD; Béla Merkely, MD, PhD; Manuel Mayr, MD, PhD

BACKGROUND: Remodeling of the extracellular matrix (ECM) is a hallmark of heart failure (HF). Our previous analysis of the secretome of murine cardiac fibroblasts returned ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) as one of the most abundant proteases. ADAMTS5 cleaves chondroitin sulfate proteoglycans such as versican. The contribution of ADAMTS5 and its substrate versican to HF is unknown.

METHODS: Versican remodeling was assessed in mice lacking the catalytic domain of ADAMTS5 (Adamts5ΔCat). Proteomics was applied to study ECM remodeling in left ventricular samples from patients with HF, with a particular focus on the effects of common medications used for the treatment of HF.

RESULTS: Versican and versikine, an ADAMTS-specific versican cleavage product, accumulated in patients with ischemic HF. Versikine was also elevated in a porcine model of cardiac ischemia/reperfusion injury and in murine hearts after angiotensin II infusion. In Adamts5ΔCat mice, angiotensin II infusion resulted in an aggravated versican build-up and hyaluronic acid disarrangement, accompanied by reduced levels of integrin β1, filamin A, and connexin 43. Echocardiographic assessment of Adamts5ΔCat mice revealed a reduced ejection fraction and an impaired global longitudinal strain on angiotensin II infusion. Cardiac hypertrophy and collagen deposition were similar to littermate controls. In a proteomics analysis of a larger cohort of cardiac explants from patients with ischemic HF (n=65), the use of β-blockers was associated with a reduction in ECM deposition, with versican being among the most pronounced changes. Subsequent experiments in cardiac fibroblasts confirmed that β1-adrenergic receptor stimulation increased versican expression. Despite similar clinical characteristics, patients with HF treated with β-blockers had a distinct cardiac ECM profile.

CONCLUSIONS: Our results in animal models and patients suggest that ADAMTS proteases are critical for versican degradation in the heart and that versican accumulation is associated with impaired cardiac function. A comprehensive characterization of the cardiac ECM in patients with ischemic HF revealed that β-blockers may have a previously unrecognized beneficial effect on cardiac chondroitin sulfate proteoglycan content.

Key Words: adrenergic beta-agonists extracellular matrix heart failure proteoglycans
Barallobre-Barreiro et al Proteoglycan Remodeling in Heart Failure

Clinical Perspective

What Is New?
- Left ventricular tissues from 80 patients with heart failure and 6 nonfailing control hearts were analyzed by quantitative mass spectrometry, constituting the largest proteomics analysis on human heart failure to date.
- Proteoglycan accumulation in ischemic heart failure was attenuated by β-blocker administration.
- Accumulation of the proteoglycan versican was regulated by ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5) and associated with a reduction in proteins involved in intercellular communication.

What Are the Clinical Implications?
- Besides their negative chronotropic and inotropic effects, β-blockers may modulate extracellular matrix remodeling.
- Proteoglycan secretion by cardiac fibroblasts constitutes an important component of cardiac fibrosis after ischemic heart failure, which contributes to impaired cardiac function.

Nonstandard Abbreviations and Acronyms

ADAMTS  a disintegrin and metalloproteinase with thrombospondin motifs
CF  cardiac fibroblast
CS  chondroitin sulfate
CSPG  chondroitin sulfate proteoglycan
ECM  extracellular matrix
GLS  global longitudinal strain
GuHCl  guanidine hydrochloride
HA  hyaluronic acid
HF  heart failure
I/R  ischemia/reperfusion
LV  left ventricle
LVEF  left ventricular ejection fraction
MS/MS  tandem mass spectrometry
scRNAseq  single-cell RNA sequencing
SDS  sodium dodecyl sulfate
STE  speckle tracking echocardiography
TMT  tandem mass tags

Recent genome-wide association studies implicated the family of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) proteases in cardiovascular diseases.3–5 In a previous proteomics study, we identified ADAMTS5 as one of the most abundant proteases secreted by mouse cardiac fibroblasts (CFs).6 ADAMTS1, ADAMTS4, and ADAMTS5 are key enzymes responsible for the degradation of chondroitin sulfate proteoglycans (CSPGs).7

Using proteomics in a porcine model of ischemia/reperfusion (I/R) injury, we have previously demonstrated that CSPGs are altered during cardiac remodeling.8 Versican is the main CSPG in the myocardium. Whereas collagens mediate force transmission and stretch resistance, CSPGs fill the extracellular space and are important for tissue hydration and signaling. Chondroitin sulfates (CS) are negatively charged, which favors electrostatic attraction of water.2,10 Accumulation of CS during pathologic remodeling can be detrimental for cardiac function.11 Moreover, versican interacts with both hyaluronic acid (HA) and the HA receptor CD44.12,13 The interaction between HA and cells is key during remodeling after myocardial infarction. For example, migration of fibroblasts and inflammatory cells is driven by CD44-dependent pathways.14

In the present study, we extend our proteomic analyses of the cardiac ECM from preclinical models5,15 to patients with ischemic HF and explore the involvement of ADAMTS5 in cardiac CSPG remodeling. Cardiac function was assessed in mice lacking the catalytic activity of ADAMTS5 (Adamts5ΔCat). We demonstrate that excessive versican deposition impairs cardiac function and alters proteins implicated in intercellular communication and that use of β-adrenoceptor antagonists (β-blockers) is associated with reduced CSPG accumulation in patients with ischemic HF.

METHODS

An expanded Methods section is available in the Supplemental Material. Proteomics datasets have been deposited in a publicly available repository as indicated in the following. All other data that support the findings of this study are available from the corresponding authors on reasonable request.

Human Cardiac Tissue

Human cardiac tissues were obtained from the Transplantation Biobank of the Heart and Vascular Center at Semmelweis University (Budapest, Hungary) and A Coruña University Hospital’s Biobank and Advanced Heart Failure and Heart Transplantation Unit (A Coruña, Spain). Cardiac tissue from patients with end-stage HF was obtained from explanted hearts during cardiac transplantation. Control tissues were obtained from unused donor hearts. Written consent was obtained from all patients enrolled in the study and institutional approvals were obtained at all source institutions (see Supplemental Material). Internal Research Ethics Committee approval was obtained at King’s College London for the use of human tissues (REC LRS-17/18–5080, REC decision entry 17440).

ECM Protein Extraction and Proteomics Analyses

ECM protein extraction was performed using our previously published method, involving sequential incubation with 0.5 M...
NaCl, 0.1% sodium dodecyl sulfate (SDS), and a final incubation with 4 M guanidine hydrochloride (GuHCl). GuHCl extracts were enzymatically deglycosylated. Label-free tandem mass spectrometry (MS/MS) analyses on GuHCl extracts were performed on a Q Exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific). SDS extracts were labeled using tandem mass tags (TMT) and analyzed on an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Scientific). MS/MS data were deposited in PRIDE (PXD024135, PXD028906, PXD028908, PXD028887, PXD028942).

Animal Experiments
All animal procedures were performed by authorized researchers. Housing and animal care was in accordance with the UK Animals (Scientific Procedures) Act 1986 and institutional ethical approval. Male Adamts5<sup>ΔCat</sup> mice (ie, lacking the catalytic domain of ADAMTS5; JAX stock 005771, B6.129P2-Adamts5<sup>Δ(1-523/1014)/J</sup>) and Adamts5<sup>+/+</sup> wild-type littermates on a C57Bl/6J background were used at 10 weeks of age for angiotensin II infusion. Murine CFs were isolated from 4- to 7-week-old C57Bl/6J mice.

Statistical Analyses
The limma package was used for all statistical comparisons using the Eabys algorithm and correcting for age and sex. Correlations were determined using Spearman correlation. For functional experiments, t tests were used for comparisons involving 2 groups, and 1-way or 2-way ANOVAs with Bonferroni corrections for comparisons involving >2 groups. Label-free MS data were normalized using the total ion intensity. TMT data were normalized against the reference channel to remove batch effects. The relative quantities of all proteins were log<sub>2</sub> transformed. All values are summarized as mean±SD or as percentages unless otherwise specified. For all significance testing, a 2-tailed P<0.05 was deemed significant.

RESULTS

ECM Composition of the Scarred Myocardium in Ischemic HF
Using proteomics in a porcine model of I/R injury, we have previously characterized the ECM in the focal injury and the border region after myocardial ischemia. In the current study, we applied a similar proteomics approach to patients with HF of ischemic origin (n=5, all male, 62.8±6.6 years). Patients with HF of nonischemic origin showing left ventricular (LV) dilatation (n=10, all male, 50.8±10.6 years) were used for comparison. Donor hearts discarded for transplantation were used as controls (n=6, all male, 49.6±2.1 years). All samples included in this comparison were obtained from A Coruña University Hospital. Diffuse fibrosis was observed in nonischemic HF; patients with ischemic HF displayed focal replacement fibrosis. Representative histologic images are presented in Figure 1A. In nonischemic and ischemic HF, a reduction in myofilament proteins MYL3 (myosin light chain 3) and TNNT3 (cardiac troponin I) was observed. In ischemic samples, this was accompanied by an increase in the fibroblast marker VIM (vimentin) and ECM proteins DCN (decorin) and DPT (dermatopontin), as well as a deposition of serum proteins, such as APCS (serum amyloid component P; Figure 1B). Similar to our previous proteomics analyses, LV tissues were subjected to a 3-step ECM extraction procedure: 0.5 M NaCl followed by 0.1% SDS for decellularization and 4 M GuHCl for extraction of core ECM proteins. A total of 200 ECM and ECM-associated proteins were identified by MS (Table S1). Besides fibrillar collagens, interstitial proteoglycans accumulated in the myocardial scar of patients with ischemic HF. These included members of the SLRP (small leucine-rich proteoglycan) family and the large aggregating proteoglycan VCAN (versican) as main CSPG (Figure 1C). Key findings of core ECM proteins in our previous analysis of a porcine model of I/R injury were replicated in patients with ischemic HF including a marked increase in VCAN (Table). In contrast, few changes in ECM abundance were detected in patients with nonischemic HF and none involved proteoglycans (Figure S1A and Table S1).

Versican and its ADAMTS-Specific Cleavage Product Versikine
In both humans and mice, versican V1 is the main cardiac isoform, followed by V0 (Figure 2A and Figure S1B). Several members of the ADAMTS family, termed hyalectanases, cleave versican. In our previous proteomics analysis of murine CFs, ADAMTS5 was the only hyalectanse identified in their secretome (Figure 2B). ADAMTS5-mediated cleavage of versican generates an N-terminal fragment, versikine, which can be detected by a neoepitope antibody (Figure S1C–S1E). The abundance of versikine is a surrogate of hyalectanase activity as well as substrate availability. Versikine staining was observed in the pericellular region of cardiomyocytes in murine hearts (Figure 2C). Versikine levels were higher in patients with HF of ischemic than nonischemic origin. Likewise, versikine was abundant in cardiac tissue from pigs subjected to I/R injury and from mice after angiotensin II infusion (Figure 2D and Figure S2A).

ADAMTS5-Mediated Versican Cleavage
To demonstrate the contribution of ADAMTS5 to cardiac versican degradation, mice with genetic deletion of the catalytic site of ADAMTS5 (Adamts5<sup>ΔCat</sup>) were subjected to angiotensin II infusion for 2 and 4 weeks. Contrary to models of acute cardiac ischemia, this model induces a more global, homogeneous, and reproducible ECM remodeling, which allows for direct assessment of cardiac function. Versican levels were markedly increased...
in Adams5\textsuperscript{\textDelta Cat} mice compared with Adams5\textsuperscript{+/+} controls, particularly at 2 but also at 4 weeks of angiotensin II infusion (Figure 3A and Figure S2B). Whereas the angiotensin II–induced increase in transforming growth factor β1 (TGFβ1) was similar to Adams5\textsuperscript{+/+} mice (Figure 3A), the induction of versican expression was less pronounced in Adams5\textsuperscript{\textDelta Cat} mice (Figure 3B, left). Angiotensin II infusion led to a reduction in Adams5 gene expression in Adams5\textsuperscript{+/+} mice (Figure 3B, right). To test whether reduced proteolytic turnover may contribute to the accumulation of versican in Adams5\textsuperscript{\textDelta Cat} mice, we probed for the ADAMTS-specific cleavage product, versikine. Versikine was undetectable in Adams5\textsuperscript{\textDelta Cat} mice even after angiotensin II infusion (Figure 3C). In contrast, collagenous fibrosis was similar to Adams5\textsuperscript{+/+} mice as indicated by Picrosirius Red staining (Figure 3D and Figure S3). No significant changes in inflammatory cell infiltration or expression of inflammatory markers (CD68 and galectin-3/LGALS3) were detected between genotypes after angiotensin II infusion (Figure S4A and S4B). Edema was present on angiotensin II infusion in subepicardial areas of both Adams5\textsuperscript{+/+} and Adams5\textsuperscript{\textDelta Cat} mice (Figure S4C).

### Cardiac Function in Adams5\textsuperscript{\textDelta Cat} Mice

To evaluate the functional consequences of CSPG accumulation in the heart, echocardiographic assessments were performed in Adams5\textsuperscript{\textDelta Cat} and Adams5\textsuperscript{+/+} mice. Representative echocardiographic images are shown in Figure S5A and S5B. LV mass as estimated by echocardiography was higher after angiotensin II infusion, but did not differ significantly between genotypes (Figure 4A). This was in agreement with the extent of cardiac hypertrophy on tissue harvesting (Figure S5C and S5D). Standard 2D ultrasound echocardiography revealed no baseline differences in LV ejection fraction % (LVEF%). On angiotensin II infusion, however, the increase in LVEF% was attenuated in Adams5\textsuperscript{\textDelta Cat} mice (Figure 4B). Similarly, global longitudinal strain (GLS) as measured by high-frequency speckle tracking echocardiography (STE\textsuperscript{19}) was impaired in Adams5\textsuperscript{\textDelta Cat} mice on
### Table. Extracellular Matrix Remodeling in Ischemic Heart Failure: Comparison With a Previous Proteomics Analysis of a Porcine Model of Ischemia and Reperfusion Injury

| Protein name | Gene name | Ischemic HF vs control | Porcine control (2 weeks) | Porcine I/R (2 months) |
|--------------|-----------|------------------------|---------------------------|-----------------------|
|              | FC        | P value                | FC                        | P value               |
| Aggrecan     | ACAN      | 6.4                    | –                         | 1.7                   | –                     | 34.0                  | 0.008*                |
| Asporin      | ASPN      | 2.7                    | 0.008*                    | 20.5                  | 0.001*                | 15.1                  | <0.001*               |
| Basement membrane-specific heparan sulfate proteoglycan | HSPG2 | 1.0                    | 0.598                     | 1.7                   | 0.220                 | 0.5                   | 0.035*                |
| Biglycan     | BGN       | 2.1                    | 0.019*                    | 22.5                  | 0.017*                | 24.8                  | 0.007*                |
| Decorin      | DCN       | 2.3                    | 0.002*                    | 1.2                   | 0.630                 | 1.0                   | 0.962                 |
| Fibromodulin | FMOD      | 12.2                   | 0.029*                    | 8.0                   | 0.135                 | 14.0                  | 0.136                 |
| Lumican      | LUM       | 2.1                    | 0.002*                    | 4.6                   | 0.014*                | 7.5                   | 0.006*                |
| Mimecan      | OGN       | 3.9                    | 0.002*                    | 16.5                  | 0.047*                | 1.7                   | –                     |
| Prolargin    | PRELP     | 2.2                    | 0.006*                    | 2.9                   | 0.035*                | 2.9                   | 0.114                 |
| Versican     | VCAN      | 2.5                    | 0.008*                    | 61.7                  | 0.009*                | 53.0                  | 0.017*                |
| Proteoglycans| Collagens |                       |                           |                       |                       |                       |                       |
| Aggrecan     | COL1A1    | 3.2                    | 0.012*                    | 4.0                   | <0.001*               | 3.8                   | 0.023*                |
| Asporin      | COL3A1    | 3.2                    | 0.003*                    | 6.0                   | 0.002*                | 6.5                   | 0.124                 |
| Biglycan     | COL5A1    | 4.1                    | 0.034*                    | 1.7                   | –                     | 5.4                   | –                     |
| Biglycan     | COL14A1   | 54.0                   | 0.002*                    | 11.1                  | 0.047*                | 20.3                  | 0.007*                |
| Biglycan     | COL16A1   | 2.2                    | –                         | 2.2                   | 0.049*                | 4.5                   | 0.038*                |
| Biglycan     | COL18A1   | 1.7                    | 0.154                    | 20.1                  | 0.049*                | 9.4                   | –                     |
| Decorin      | COL1A2    | 2.9                    | 0.010*                    | 2.2                   | 0.146                 | 2.9                   | –                     |
| Decorin      | COL5A2    | 3.6                    | 0.018*                    | 4.8                   | –                     | 9.7                   | <0.001*               |
| Collagens    | Other ECM proteins |                       |                           |                       |                       |                       |                       |
| Annexin A2   | ANXA2     | 1.4                    | 0.342                     | 15.4                  | 0.002*                | 10.5                  | 0.216                 |
| Cartilage intermediate layer protein 1 | COL1P | 16.2                   | 0.090                     | 30.5                  | <0.001*               | 11.6                  | <0.001*               |
| Dermatopontin | DPT      | 3.7                    | 0.005*                    | 4.1                   | 0.020*                | 3.4                   | 0.005*                |
| EMILIN-1     | EMILIN1   | 7.2                    | 0.006*                    | 3.6                   | 0.136                 | 3.6                   | 0.108                 |
| Fibronectin  | FN1       | 1.7                    | 0.030*                    | 36.5                  | 0.068                 | 21.3                  | 0.187                 |
| Insulin-like growth factor-binding protein 7 | IGFBP7 | 2.3                    | 0.005*                    | 3.6                   | 0.136                 | 2.9                   | 0.195                 |
| Laminin subunit α-2 | LAMA2 | 0.8                    | 0.219                     | 1.3                   | 0.680                 | 0.1                   | 0.048*                |
| Laminin subunit β-2 | LAMB2 | 1.0                    | 0.544                     | 0.9                   | 0.763                 | 0.2                   | 0.006*                |
| Latent-transforming growth factor β-binding protein 2 | LTB2 | 24.2                   | <0.001*                   |                       |                       |                       |                       |
| Latent-transforming growth factor β-binding protein 4 | LTB4 | 13.4                   | 0.011*                    |                       |                       |                       |                       |
| Nidogen-1    | NID1      | 1.0                    | 0.873                     | 0.6                   | 0.572                 | 0.2                   | 0.050*                |
| Periostin    | POSTN     | 8.4                    | 0.020*                    | 9.9                   | 0.003*                | 19.5                  | 0.039*                |
| Target of Nesh-SH3 | AB38P | 6.2                    | 0.009*                    | 3.7                   | 0.157                 | 5.7                   | 0.054                 |
| Tenasin      | TNC       | 16.4                   | 0.069                     | 44.8                  | 0.040*                | 37.4                  | 0.072                 |
| Tetranectin  | CLEC3B    | 3.1                    | 0.012*                    | 5.8                   | 0.008*                | 6.7                   | 0.038*                |
| Thrombospondin type-1 domain-containing protein 4 | THSD4 | 3.3                    | 0.013*                    |                       |                       |                       |                       |
| Transforming growth factor β-induced protein ig-h3 | TGFBI | 1.8                    | 0.208                     | 23.4                  | 0.004*                | 7.4                   | <0.001*               |

*Significant \( P < 0.05 \).
angiotensin II treatment (Figure 4C). Diastolic function as assessed by reverse-longitudinal strain rate and left atrial size in echocardiography was not different. A summary of echocardiographic measurements is provided in Table S2.

**Pericellular Accumulation of ECM**

Lack of ADAMTS5 activity predominantly resulted in cardiac versican accumulation on angiotensin II infusion (Figure S6A and S6B and Table S3). Versican binds to HA through its HA-binding domain and is an important regulator of HA remodeling in the heart (Figure 4D). Gene expression levels of HA-degrading enzymes (hyaluronidases, HYAL1, and HYAL2) and HA synthases (HYAS1, HYAS2, and HYAS3) were similar in Adamts5$^{-/-}$ and Adamts5$^{+/+}$ mice (Figure S6C). Adamts5$^{+/+}$ mice, however, displayed a higher HA content on angiotensin II infusion (Figure 4E and Figure S6D). Because pericellular versican and HA accumulation may affect cell–cell communication, we determined levels of proteins involved in cardiac cell adhesion and communication. In response to angiotensin II infusion, ITB1 (integrin $\beta_1$), FLNA (filamin A), and CNX43 (connexin 43) were increased in hearts of Adamts5$^{+/+}$ mice. In Adamts5$^{-/-}$ mice, however, this response was blunted even after 4 weeks of angiotensin II infusion (Figure 4F). Thus, loss of ADAMTS5 activity reduces the abundance of cardiac proteins implicated in cell–cell communication (Figure 4G).

**Versican and ADAMTS Expression in Human Hearts**

In a single-cell RNA sequencing (scRNAseq) dataset from different human cardiac regions, expression of versican was mainly restricted to CFs. Consistent with our
Barallobre-Barreiro et al. Proteoglycan Remodeling in Heart Failure

previous proteomics results in mouse CFs, ADAMTS5 was the main ADAMTS expressed in CFs (Figure 5A). In the heart, ADAMTS1 was expressed in endothelial cells, pericytes and smooth muscle cells, and ADAMTS4 was abundant only in pericytes and smooth muscle cells (Figure S7A). Among the different CF populations (Figure 5B), including ECM-producing and ECM-remodeling CFs, all expressed versican in abundance. ADAMTS5 expression, however, was mainly restricted to a specific subgroup of CFs. This population (FB1) was the main contributor to the ventricular CF pool and was distinct from the predominant CF population in atria (FB2; Figure S7B and S7C). Ventricular CFs had comparatively higher expression levels of ADAMTS5 and lower expression of versican (Figure 5C and Figure S8A and S8B). A proteomics comparison of human LV and left atrial tissues from unused donor hearts (n=7 each, obtained from A Coruña University Hospital) showed lower levels of versican in LV (Figure S8C).

Effects of Medication on the ECM Composition in Ischemic HF

Next, LV tissues from a larger cohort of patients with ischemic HF (n=65, obtained from the Transplantation Biobank of the Heart and Vascular Center at Semmelweis University) were subject to proteomics analysis. Of 177 ECM and ECM-associated proteins in the ECM-enriched fractions (4 M GuHCl extracts; Table S4), 141 (79.7%) were suitable for quantification. The 0.1% SDS extracts containing predominantly intracellular proteins were analyzed by multiplexed proteomics (Table S5). Age- and sex-corrected comparisons based on comorbidities and long-term medications are shown in Tables S6 and S7. Use of β-blockers returned the highest number of altered proteins in both extracts (Figure 6A). Enrichment analysis using Gene Ontology annotation, Reactome, and Kyoto Encyclopedia of Genes and Genomes pathway databases (0.1% SDS extracts, Table S8), returned terms related...
Proteoglycan Remodeling in Heart Failure

Barallobre-Barreiro et al

To ECM synthesis and processing for use of β-blockers (Figure 6B). In contrast, few changes were observed with statins, in particular in the ECM-enriched fraction (4 M GuHCl extracts; Figure 6A). Instead, statin use was associated with terms related to metabolism (Figure 6B). Among ECM proteins, patients with ischemic HF on β-blockers showed predominantly a reduced abundance of proteoglycans. Both SLRPs as well as VCAN and its
fragmentation product, versikine, were affected (Figure 6C, Table S6, and Figure S9A). CD44, the main receptor for HA, was also reduced with β-blocker usage (see Table S7). Heart rate showed a positive correlation with cardiac ECM protein abundance (see Table S9), with versican protein abundance displaying the strongest correlation (Figure S9B). In contrast, there were no significant changes in mRNA expression levels (Figure S9C).

**Noradrenalin Induces Versican Expression in CFs**

To explore potential direct effects of β-adrenergic signaling on CFs, we treated mouse ventricular CFs with noradrenaline. TGFβ1 treatment was used for comparison (Figure S10A). The reduction in Adams5 expression in TGFβ1-treated CFs was consistent with our
observations in angiotensin II–treated mice, where an increase in pre-TGFβ1 accompanied versican accumulation (see Figure 3A and 3B). Treatment with noradrenaline increased versican expression. Unlike TGFβ1, noradrenaline did not affect Adamts5 (Figure 6D, left).

Treatment of murine CFs with the β1-selective adreno-receptor antagonist bisoprolol blocked the noradrenaline-induced upregulation of versican expression in CFs from both female and male mice, demonstrating a direct effect of β-blockers in regulating this key proteoglycan (Figure 6D, right). Again, Adamts5 expression was not affected (Figure S10B). Similarly, administration of bisoprolol for 2 weeks reduced versican expression in murine hearts (Figure 6E), with no effect on gene expression levels of Adamts5 (Figure S10C).

**Clustering Analysis of Ischemic HF**

Clustering analyses based on protein-to-protein correlation of abundance returned a dense cluster of fibroblast-secreted interstitial ECM proteins. Versican was central to this cluster, as were the majority of ECM proteins showing changes in patients on β-blockers. A second cluster comprised ECM proteins associated with...
the basement membrane of nonfibroblasts (Figure 7A). In a principal component analysis, clinical variables did not separate patients on β-blockers from those without. However, when ECM proteomic profiles were used, a good separation was obtained (Figure 7B and Figure S11A). The first principal component (PCA1), accounting for 22.5% of the variability, determined the best separation between patients with and without β-blockers (Figure 7C and Figure S11B) and was mainly dependent on proteoglycan abundance (Figure S11C). No significant separation was obtained for other medications (data not shown). Thus, β-blockers reduce cardiac ECM deposition, independent of other clinical variables, with proteoglycans being most affected.

**DISCUSSION**

This study generated several novel findings. First, using proteomics, we obtained an unprecedented depth of coverage for the human cardiac ECM. We confirmed our previous findings in a porcine model of I/R injury by demonstrating that versican and other proteoglycans also accumulate in the scarred myocardium of patients with ischemic HF. Second, we confirmed that ADAMTS proteases cleave versican during cardiac remodeling. Third, we demonstrated that versican accumulation in Adamts5ΔCat mice was associated with impaired cardiac function and a reduction in proteins involved in cell–cell communication. Last, we explored the effect of medications on ECM remodeling and revealed that β-blockers attenuate versican accumulation in ischemic HF.

**CSPGs in the Cardiac ECM**

CSPGs are critical components of the ECM. Aggrecan is the major proteoglycan of cartilage tissue. Brevican and neurocan are essential components of the ECM in nervous tissues. Versican is the predominant CSPG in the heart, with CFs being the main source. Whereas genetic deletion of other CSPGs results in viable mice until birth, mice deficient in versican die embryonically and display major cardiovascular defects. Even partial deletion of the N-terminal G1 domain of versican is detrimental to the heart. Notwithstanding the importance of collagens in cardiac remodeling, the contribution of CSPGs may be underestimated given the challenges in detection of these highly glycanated proteins using antibody-based methods. Proteomics studies analyzing human cardiac ECM tend to be performed without deglycosylation, resulting in incomplete coverage and possibly inaccurate quantification by mass spectrometry. Thus, we used stringent buffer conditions that allow for efficient extraction of CSPGs, followed by deglycosylation of the ECM extracts before proteomics analysis.

**Role of ADAMTS5 in the Heart**

A constant turnover of versican is required to avoid accumulation as shown in different tissues. The VCAN/ADAMTS5 axis emerged as an important determinant for cardiac ECM composition. On the basis of the scRNA-seq data from 2 cardiac regions of human hearts, the CF subsets enriched in ADAMTS5 are the least enriched for VCAN. Thus, there is an inverse correlation between the gene expression of the protease and its main substrate. In mice, ADAMTS-mediated cleavage of versican is dependent on ADAMTS5. In wild-type mice, angiotensin II infusion reduced cardiac ADAMTS5 expression. In Adamts5ΔCat mice, loss of ADAMTS5 activity was sufficient to exacerbate the cardiac buildup of versican and HA. The former observation was supported by our finding that versikine, an ADAMTS-specific versican fragment, was absent...
in Adams5\textsuperscript{ACat} mice. Versican binds to HA through the G1 domain contained within versikine.\textsuperscript{26} Without cleavage by ADAMTS5, versican–HA complexes cannot be readily accessed by other versican-degrading enzymes, leading to accumulation of versican–HA aggregates.\textsuperscript{26}

**Effect of ADAMTS5 on Cardiac Function**

Adams5\textsuperscript{ACat} mice have normal baseline cardiac function, in line with a previous report.\textsuperscript{27} In response to angiotensin II treatment, their increase in LV mass was similar to littermate controls. The accumulation of versican–HA aggregates, however, was associated with reduced LVEF and impaired GLS in Adams5\textsuperscript{ACat} mice. Versican contains between 12 and 23 CS chains, depending on the isoform,\textsuperscript{30} and is a major contributor to the CS content in the heart. In a mouse model of cardiac I/R injury, CSPGs in the scar area prevented sympathetic reinnervation, and treatment with chondroitinase was sufficient to overcome this effect.\textsuperscript{38} The accumulation of versican–HA aggregates may also alter cell–cell communication.\textsuperscript{21} First, the angiotensin II–induced upregulation of connexin 43 and integrin \(\beta 1\) was blunted in Adams5\textsuperscript{ACat} mice. Both connexin 43 and integrin \(\beta 1\) are localized at intercalated discs and costameres. \(\beta 1\) integrins have been implicated as a stiffness mechanosensor.\textsuperscript{39} Reductions in connexin 43 have been reported in advanced HF stages.\textsuperscript{32} Second, migration of CFs and inflammatory cells is regulated by CD44-dependent pathways,\textsuperscript{14} the main receptor for HA. HA size is an important factor determining the recruitment of inflammatory cells,\textsuperscript{40} and versikine can induce macrophage polarization.\textsuperscript{41} Third, HA synthesis contributes to postinfarct healing by supporting myofibroblast response during the first days after myocardial infarction.\textsuperscript{42}

**Effect of Medications in Ischemic HF**

Our proteomics analysis in a larger cohort of patients with ischemic HF (\(n=65\)) revealed that versican levels were significantly reduced on treatment with \(\beta\)-blockers. Previous proteomics studies using human cardiac tissue were not designed for the study of ECM proteins\textsuperscript{43} or were too small to assess the effects of medications.\textsuperscript{15,30,32,43,44} Given the negative inotropic and chronotropic effects of \(\beta\)-blockers, the reduction of versican could be an indirect effect. In a rat model of chronic ischemic HF, ivabradine resulted in a marked attenuation of cardiac fibrosis.\textsuperscript{45} Ivabradine is a cardiotonic agent and reduces the heart rate through mechanisms that are distinct from \(\beta\)-blockers. We observed a positive correlation between heart rate and versican protein abundance. Thus, the effect of \(\beta\)-blockers on the cardiac ECM could be attributed to their negative inotropic and chronotropic activity. On the other hand, \(\beta\)-adrenergic stimulation of CFs may have direct effects. \(\beta 1\)-adrenoceptor stimulation has been shown to induce synthesis of collagen 1 and fibronectin in CFs isolated from neonatal rats.\textsuperscript{46,47} We now demonstrate that noradrenaline stimulation induces versican expression in adult murine CFs through \(\beta 1\) adrenoceptor-dependent mechanisms. Thus, in addition to affecting cardiomyocytes, \(\beta\)-blockers may directly affect CFs.

**Limitations**

Whereas ADAMTS5 has a high specificity for CSPGs,\textsuperscript{18} other targets could be affected by loss of ADAMTS5 activity. Approximately 12% of Adams5\textsuperscript{ACat} mice have bicuspid aortic valves.\textsuperscript{48} Thus, all mice with valve defects were excluded from our experiments. We have previously reported an attenuated rise in blood pressure in Adams5\textsuperscript{ACat} mice on angiotensin II infusion.\textsuperscript{17} Whereas blood pressure is an important determinant of cardiac remodeling and cardiac function, reduced blood pressure would only reduce any prohypertrophic effects, supporting a direct cardiac effect of ADAMTS5 deficiency. A reduced blood pressure in Adams5\textsuperscript{ACat} compared with Adams5\textsuperscript{+/+} mice was also observed by Hemmeryckx et al,\textsuperscript{37} with no differences in associated cardiac phenotypes on feeding a high-fat diet. We used HF tissue from end-stage explanted failing hearts, which might be different from less severe human HF. However, myocardial samples from the latter group are difficult to procure.

**Conclusions**

Besides collagen deposition, CSPG deposition can be detrimental to cardiac function. We provide evidence that ADAMTS proteases, in particular ADAMTS5, control versican turnover. Buildup of versican in Adams5\textsuperscript{ACat} mice on angiotensin II infusion resulted in HA accumulation, which was accompanied by compromised cardiac function and a decrease in proteins implicated in cell–cell communication. Use of \(\beta\)-blockers was associated with reduced CSPG deposition in patients with ischemic HF. The effects of \(\beta\)-blockers on nonmyocytes and the composition of the cardiac ECM deserve further investigation in HF.

**ARTICLE INFORMATION**

Received June 4, 2021; accepted October 20, 2021.

**Affiliations**

King's BHF Centre of Research Excellence, London, UK (J.B.-B., MF, UM, W.-YL, EE, ED, MH, L.E.S, BS, RL, FB, AM:S, N.C, KT, AMS, MM); Heart and Vascular Center, Department of Cardiology, Semmelweis University, Budapest, Hungary (TR, LD, BM); Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (W-Y.L.); IIS-Fundación Jiménez Díaz–Universidad Autónoma de CIBERCV, Madrid, Spain (D.M.-L.); Max Debrueck Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (E.L.L., N.H.); Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, German Center for Heart Research (DZHK), Hamburg, Germany (F.O., Instituto de Investigación Biomédica de A Coruña (INIBIC)-CIBERCV, Complexo Hospitalario Universitario de A Coruña (CHUAC), Universidad da Coruña, Spain (M.G.C.-L., N.D.). Charité-Universitätsmedizin, Berlin, Germany (F.C.). Instituto de Investigación Biomédica de A Coruña (INIBIC)–CIBERCV, Complexo Hospitalario Universitario de A Coruña (CHUAC), Universidade da Coruña, Spain (M.G.C.-L., N.D.). Charité-Universitätsmedizin, Berlin,
Barallobre-Barreiro et al Proteoglycan Remodeling in Heart Failure

29. Hatano S, Kimata K, Hiraïwa N, Kusakabe M, Isogai Z, Adachi E, Shinomura T, Watanabe H. Versican/PG-M is essential for ventricular septal formation subsequent to cardiac atriовentricular cushion development. Glycobiology. 2012;22:1268–1277. doi: 10.1093/glycob/cws095

30. Lindsey ML, Iyer RP, Zampliška R, Yablochanskiy A, DeLeon-Pennell KY, Hall ME, Kaplan A, Zouein FA, Bratton D, Flynn ER, et al. A novel collagen matrixprin reduces left ventricular dilatation post-myocardial infarction by promoting scar formation and angiogenesis. J Am Coll Cardiol. 2015;66:1364–1374. doi: 10.1016/j.jacc.2015.07.0305

31. Barallobre-Barreiro J, Lynch M, Yin X, Mayr M. Systems biology-opportunities and challenges: the application of proteomics to study the cardiovascular extracellular matrix. Cardiovac. Res. 2016;112:24–66. doi: 10.1093/cvr/cwv206

32. Perestrello AR, Silva AC, Oliver-De La Cruz J, Martino F, Horváth V, Caluori G, Polansky O, Vinarsky V, Azzato G, de Marco G, et al. Multiscale analysis of extracellular matrix remodeling in the failing heart. Circ. Res. 2018;121:28–38. doi: 10.1161/CIRCRESAHA.120.317685

33. Sura G, Wojakowski W, Lynch M, Barallobre-Barreiro J, Yin X, Mayr U, Bada G, Lu R, Fava M, Hayward R, et al. Extracellular matrix proteomics reveals interplay of aggrecan and aggrecanases in vascular remodeling of stented coronary arteries. Circulation. 2018;137:166–183. doi: 10.1161/CIRCULATIONAHA.116.023381

34. Cikach FS, Koch CD, Mead TJ, Galatioto J, Willard BB, Emerton KB, Lindsey ML, Iyer RP, Zamilpa R, Yabluchanskiy A, DeLeon-Pennell KY, et al. Extracellular matrix proteomics of myocardial ischemia and reperfusion injury. JCI Insight. 2021;6:32430. doi: 10.1172/jci.insight.97167

35. Hattori N, Carrino DA, Lauer ME, Vasanji A, Wylie JD, Nelson CM, Apte SS. The multiple, complex roles of versican in injury. Circ Res. 2019;124:1433–1447. doi: 10.1161/CIRCRESAHA.118.313285

36. Hattori N, Carrino DA, Lauer ME, Vasanji A, Wylie JD, Nelson CM, Apte SS. The multiple, complex roles of versican in injury. Circ Res. 2019;124:1433–1447. doi: 10.1161/CIRCRESAHA.118.313285

37. Hemmeryckx B, Carai P, Roger Lijnen H. ADAMTS5 deficiency in mice does not affect cardiac function. J Mol Cell Cardiol. 2013;60:50–59. doi: 10.1016/j.yjmcc.2013.03.010

38. Dupuis LE, Osińska H, Weinstein MB, Hinton RB, Kern CB. Insufficient versican cleavage and Smad2 phosphorylation results in bicuspid aortic and pulmonary valves. J Mol Cell Cardiol. 2013;60:50–59. doi: 10.1016/j.yjmcc.2013.03.010

39. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor: Statistics for Biology and Health. Springer; 2005:397–420. doi: 10.1007/0-387-29362-0_23

40. Wuchty S, Ravasz E, Barabási AL. The architecture of biological networks. Science. 2006;70:422–433. doi: 10.1016/j.cardiores.2005.12.015

41. Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakis K, Callander N, Miyamoto S, et al. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016;128:680–685. doi: 10.1182/blood-2016-03-705780

42. Petz A, Grandoch M, Gorski DJ, Abrams M, Piroth M, Schneckenmann R, Homann S, Müller J, Hartwig S, Lehr S, et al. Cardiac hyaluronan synthesis is critically involved in the cardiac macrophage response and promotes healing after ischemia-reperfusion injury. Circ. Res. 2019;124:1433–1447. doi: 10.1161/CIRCRESAHA.118.313285

43. Li M, Parker BL, Pearson E, Hunter B, Cao J, Koay YC, Guneratne O, James DE, Yang J, Lal S, et al. Core functional nodes and sex-specific pathways in human ischaemic and dilated cardiomyopathy. Nat Commun. 2020;11:2843. doi: 10.1038/s41467-020-16584-z

44. Parker BL, Palmisano G, Edwards AV, White MY, Engholm-Keller K, Lee A, Scott NE, Kolarich D, Hambly BD, Packard NH, et al. Quantitative N-linked glycoproteomics of myocardial ischemia and reperfusion injury reveals early remodeling in the extracellular environment. Mol Cell Proteomics. 2011;10:M110.006833. doi: 10.1074/mcp.M110.006833

45. Milettz P, Messiaud S, Nemhe J, Rodrigue C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart. 2009;296:H435–H441. doi: 10.1152/ajpheart.00591.2008

46. Lv T, Du Y, Cao N, Zhang S, Gong Y, Bai Y, Wang W, Liu H. Proliferation in cardiac fibroblasts caused by β-adrenoceptor autoantibody and the underlying mechanisms. Sci Rep. 2016;6:32430. doi: 10.1038/srep32430

47. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A, Seto S, Tsukazaki T, Kikuchi H, Yamashita S, Yano K. Norepinephrine enhances fibrosis mediated by β-adrenoceptor autoantibody and the underlying mechanisms. Sci Rep. 2016;6:32430. doi: 10.1038/srep32430

48. Dupuis LE, Osińska H, Weinstein MB, Hinton RB, Kern CB. Insufficient versican cleavage and Smad2 phosphorylation results in bicuspid aortic and pulmonary valves. J Mol Cell Cardiol. 2013;60:50–59. doi: 10.1016/j.yjmcc.2013.03.010

49. Hemmeryckx B, Carai P, Roger Lijnen H. ADAMTS5 deficiency in mice does not affect cardiac function. Cell Biol Int. 2013;43:593–604. doi: 10.1002/cbin.11130

50. Gardner RT, Habecker BA. Infarct-derived chondroitin sulfate proteoglycans prevent sympathetic reinnervation after cardiac ischemia-reperfusion injury. J Neurosci. 2013;33:7175–7183. doi: 10.1523/JNEUROSCI.685.2013

51. Branchi M, Hirsch E, Nottle A, Selvetti G, Lombo G, Tarone G. Integrin signalling: the tug-of-war in heart hypertrophy. Cardiovac. Res. 2006;70:422–433. doi: 10.1016/j.cardiores.2005.12.015

52. Barallobre-Barreiro et al Proteoglycan Remodeling in Heart Failure